NASDAQ:SNTI Senti Biosciences Q4 2025 Earnings Report $0.35 +0.02 (+7.07%) Closing price 10/5/2026 04:00 PM EasternExtended Trading$0.34 -0.01 (-2.93%) As of 10/5/2026 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Senti Biosciences EPS ResultsActual EPS-$0.53Consensus EPS -$0.43Beat/MissMissed by -$0.10One Year Ago EPSN/ASenti Biosciences Revenue ResultsActual RevenueN/AExpected Revenue$1.00 millionBeat/MissN/AYoY Revenue GrowthN/ASenti Biosciences Announcement DetailsQuarterQ4 2025Date3/27/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsSenti Biosciences' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Senti Biosciences Earnings HeadlinesWhat is HC Wainwright's Forecast for SNTI Q3 Earnings?September 27, 2026 | americanbankingnews.comSenti Biosciences Holdings IncAugust 11, 2026 | cnn.comYour backdoor link (still works)Bill Poulos is offering a private link to download his book Simple Options Trading For Beginners, bypassing the usual $29.97 checkout entirely. The page isn't listed anywhere on his site. Once it closes, the standard checkout becomes the only way in. | Profits Run (Ad)Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next ...July 15, 2026 | markets.businessinsider.comSenti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology PlatformJuly 15, 2026 | globenewswire.comSenti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note StructureMay 16, 2026 | tipranks.comSee More Senti Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Senti Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Senti Biosciences and other key companies, straight to your email. Email Address About Senti BiosciencesSenti Biosciences (NASDAQ:SNTI) is a biotechnology company focused on developing programmable cell and gene therapies. Its technology platform uses synthetic biology and genetic circuits to engineer cells that can recognize disease-related signals and activate therapeutic functions in a controlled manner. The company’s development programs have included engineered immune-cell therapies, including CAR-NK and other cell-based treatments designed for oncology applications. Senti Bio has also developed gene-circuit technologies intended to improve the targeting, safety and activity of therapeutic cells, with potential applications in cancer and other serious diseases. Founded in 2016 and headquartered in San Francisco, California, Senti Bio has worked with biotechnology and pharmaceutical partners to advance its platform and therapeutic candidates. The company became publicly traded on Nasdaq in 2022 following a business combination with a special purpose acquisition company. Its programs and collaborations have primarily centered on developing next-generation cell therapies for patients with limited treatment options.View Senti Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last Longer Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
